|
|
|
|
|
|
|
 |
[t(8;21)(q22;q22)] translocation generates the formation of gene fusion between the ETO gene on chromosome 8 and the AML1 gene on chromosome 21 and turns out to be present in 20~40 % of acute myelogenous leukemia (AML (M4)) cases. If the disease recurs at a long term after bone marrow transplantation, the fusion gene will continuously be observed. Chromosome tests usually result in high false negative rate as well as unexplainable mosaic forms of chromosome and require a sufficient amount of cells at division stage and require significant time and effort. Even though RT-PCR can be performed even with a limited amount of specimen, using conventional primers require additional nested PCR steps to detect AML1/ETO after initial RT-PCR.
Seeplex® Leukemia AML1/ETO ACE detects the AML1/ETO fusion gene with only one PCR reaction after cDNA synthesis using DPO™ technology, which maximizes specificity and sensitivity.
- Detection limit:
10 copies (100% detection),
5 copies (80% detection) |
 |
| A. |
Multiplex PCR with high sensitivity and specificity by applying DPO™ (Dual Priming Oligonucleotide) technology |
|
DPO™-based primers contain two priming parts so that only target gene is specifically amplified. |
| B. |
Applicable for Auto-capillary Electrophoresis device |
|
PCR amplicons are separated and analyzed automatically; consequently, rapid and easy interpretation of the results is possible. |
|
| |
| C. |
Contamination Prevention System |
|
One-time PCR reduces the carryover contamination risk, and 8-MOP, which is included in product, eliminates the contamination risk from PCR. |
| D. |
Accurate system for interpretation of results |
|
Internal Control and Positive Control are included in product. |
|
|
|
 |
 |
ScreenTape®
System
(Agilent
Technologies)
 |
 |
MCE®-202
MultiNA
SHIMADZU
|
|
|
|
 |
|
 |
- Whole blood
- Bone marrow
|
|
- AML1/ETO fusion gene [t(8;21)(q22;q22)] |
|
 |
| Product |
Cat. No. |
Size |
| Seeplex® Leukemia AML/ETO ACE |
AM1110Z |
25 rxns |
|
|
|
|
|
|
